Psoriatic Arthritis
Conditions
Keywords
psoriatic arthritis, tofacitinib, ACR20, HAQ-DI, TNF inhibitor failure
Brief summary
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
Interventions
DRUGTofacitinib
tablets, 5 mg BID x 6 months
OTHERPlacebo
tablets, to match tofacitinib 5 mg BID x 3 months
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints * Active plaque psoriasis at screening * Inadequate efficacy or lack of toleration to previously administered TNF inhibitor
Exclusion criteria
* Non-plaque forms of psoriasis (with exception of nail psoriasis) * History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 | Month 3 | ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP). |
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3 | Month 3 | The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Week 2 and Months 1, 2, 4, and 6 | ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders. |
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Week 2 and Months 1, 2, 4, and 6 | The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. n=number of participants evaluable at each visit. |
| Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3 | Month 3 | The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. |
| Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3 | Month 3 | Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. |
| Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3 | Month 3 | Participants answered the following question, Considering all the ways your arthritis affects you, how are you feeling today? The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly). |
| Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3 | Month 3 | The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor). |
| Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3 | Month 3 | Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling. |
| Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3 | Month 3 | Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful. |
| Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Week 2, Months 1, 2, 3, 4, and 6 | The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders. |
| Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Months 1, 3, and 6 | The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). n=number of participants evaluable at each visit. |
| Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Months 1, 3, and 6 | PASI determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, and scaling evaluated separately for the head and neck, upper limbs, trunk, and lower limbs and then rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is assigned a numerical score: 0=no involvement; 1=0% to 9%; 2=10% to 29%; 3=30% to 49%; 4=50% to 69%; 5=70% to 89%; 6=90% to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a 75% reduction from baseline in PASI. n=number of responders. |
| Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Months 1, 3, and 6 | Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. n=number of participants evaluable at each visit. |
| Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Months 1, 3, and 6 | The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. n=number of participants evaluable at each visit. |
| Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Months 1, 3, and 6 | Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better mental health status. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Months 1, 3, 6 | SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 10 items of the physical functioning scale represent levels & kinds of limitations between extremes of physical activities, including lifting & carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence & extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher physical functioning domain score represents better physical functioning. n=number of participants evaluable at each visit. |
| Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 and Months 1, 2, 3, 4, and 6 | ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher bodily pain domain score represents less bodily pain. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher general health domain score represents better general health perceptions. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher vitality domain score represents better vitality. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher social functioning domain score represents better social functioning. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher role-emotional domain score represents better role-emotional functioning. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Months 1, 3, 6 | The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher mental health domain score represents better mental health functioning. n=number of participants evaluable at each visit. |
| Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Months 1, 3, 6 | The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit. |
| Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Months 1, 3, 6 | The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit. |
| Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Months 1, 3, 6 | The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit. |
| Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Months 1, 3, 6 | The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit. |
| Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Months 1, 3, 6 | The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit. |
| Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Months 1, 3, 6 | The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit. |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Months 1, 3, 6 | FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (washed out), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status. n=number of participants evaluable at each visit. |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Months 1, 3, 6 | FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (washed out), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience. n=number of participants evaluable at each visit. |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Months 1, 3, 6 | FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (washed out), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning. n=number of participants evaluable at each visit. |
| Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Months 1, 3, 6 | BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity. n=number of participants evaluable at each visit. |
| Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Months 1, 3, 6 | SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; & d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher role-physical domain score represents better role-physical functioning. n=number of participants evaluable at each visit. |
| Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 and Months 1, 2, 3, 4, and 6 | ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders. |
Countries
Australia, Belgium, Brazil, Czechia, France, Germany, Mexico, Poland, Russia, Slovakia, Spain, Taiwan, United Kingdom, United States
Participant flow
Recruitment details
Data through End of Study (Month 6)
Pre-assignment details
Of 546 participants screened for entry into the study, 395 were enrolled and randomized, 394 received treatment.
Participants by arm
| Arm | Count |
|---|---|
| Tofacitinib, 5 mg Twice Daily Participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet twice daily. | 131 |
| Tofacitinib, 10 mg, Twice Daily Participants received two 5 mg tofacitinib tablets, twice daily. | 132 |
| Placebo/Tofacitinib, 5 mg, Twice Daily Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received one 5 mg tofacitinib tablet, twice daily, and one placebo tablet, twice daily. | 66 |
| Placebo/Tofacitinib, 10 mg, Twice Daily Participants received two placebo tablets, twice daily, up to 3 months. At the end of this period, participants received two 5 mg tofacitinib tablets, twice daily. | 65 |
| Total | 394 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse event related to study drug | 3 | 8 | 1 | 2 |
| Overall Study | Adverse event unrelated to study drug | 2 | 2 | 1 | 1 |
| Overall Study | Insufficient clinical response | 1 | 4 | 4 | 2 |
| Overall Study | Medication error with no associated AE | 0 | 0 | 2 | 0 |
| Overall Study | No longer willing to participate | 1 | 4 | 2 | 3 |
| Overall Study | Pregnancy | 0 | 1 | 0 | 0 |
| Overall Study | Protocol Violation | 2 | 2 | 0 | 1 |
Baseline characteristics
| Characteristic | Tofacitinib, 5 mg Twice Daily | Tofacitinib, 10 mg, Twice Daily | Placebo/Tofacitinib, 5 mg, Twice Daily | Placebo/Tofacitinib, 10 mg, Twice Daily | Total |
|---|---|---|---|---|---|
| Age, Continuous | 49.5 Years STANDARD_DEVIATION 12.3 | 51.3 Years STANDARD_DEVIATION 10.9 | 48.7 Years STANDARD_DEVIATION 11.2 | 49.3 Years STANDARD_DEVIATION 14 | 50.0 Years STANDARD_DEVIATION 12 |
| Sex: Female, Male Female | 64 Participants | 74 Participants | 38 Participants | 42 Participants | 218 Participants |
| Sex: Female, Male Male | 67 Participants | 58 Participants | 28 Participants | 23 Participants | 176 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 49 / 131 | 48 / 132 | 19 / 66 | 19 / 65 |
| serious Total, serious adverse events | 5 / 131 | 8 / 132 | 2 / 66 | 1 / 65 |
Outcome results
Primary
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3
The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3 | -0.3920 Units on a scale | Standard Error 0.04544 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3 | -0.3540 Units on a scale | Standard Error 0.04579 |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3 | -0.1391 Units on a scale | Standard Error 0.04573 |
p-value: <0.000195% CI: [-0.3792, -0.1266]Mixed Models Analysis
p-value: 0.000995% CI: [-0.3419, -0.0881]Mixed Models Analysis
Primary
Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3
ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP).
Time frame: Month 3
Population: All participants who were randomized and received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 | 49.62 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 | 46.97 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 | 23.66 Percentage of participants |
p-value: <0.000195% CI: [14.72, 37.19]Large sample approximation
p-value: <0.000195% CI: [12.1, 34.51]Large sample approximation
Secondary
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3 | -5.4657 mg/L | Standard Error 1.80096 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3 | -5.9156 mg/L | Standard Error 1.83181 |
| Placebo | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3 | 1.0233 mg/L | Standard Error 1.82879 |
Secondary
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3
Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3 | -21.66 mm | Standard Error 2.162 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3 | -20.88 mm | Standard Error 2.188 |
| Placebo | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3 | -7.72 mm | Standard Error 2.184 |
Secondary
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3
Participants answered the following question, Considering all the ways your arthritis affects you, how are you feeling today? The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3 | -21.59 mm | Standard Error 2.228 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3 | -19.88 mm | Standard Error 2.248 |
| Placebo | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3 | -7.14 mm | Standard Error 2.247 |
Secondary
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3
The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3 | -27.25 mm | Standard Error 1.893 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3 | -28.95 mm | Standard Error 1.916 |
| Placebo | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3 | -15.88 mm | Standard Error 1.929 |
Secondary
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3
Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3 | -7.6 Joints | Standard Error 0.59 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3 | -6.7 Joints | Standard Error 0.6 |
| Placebo | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3 | -2.7 Joints | Standard Error 0.6 |
Secondary
Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3
Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.
Time frame: Month 3
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3 | -9.9 Joints | Standard Error 0.97 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3 | -9.7 Joints | Standard Error 0.98 |
| Placebo | Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3 | -4.5 Joints | Standard Error 0.98 |
Secondary
Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6
Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, and 6
Population: All participants who were randomized, received at least 1 dose of study drug with baseline DSS \>0, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 6 (n=61,55,25,26,NA) | -6.0 Units on a scale | Standard Error 0.84 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 3 (n=64,58,NA,NA,55) | -5.2 Units on a scale | Standard Error 0.73 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 1 (n=65,64,NA,NA,62) | -2.8 Units on a scale | Standard Error 0.63 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 6 (n=61,55,25,26,NA) | -6.0 Units on a scale | Standard Error 0.9 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 1 (n=65,64,NA,NA,62) | -4.0 Units on a scale | Standard Error 0.65 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 3 (n=64,58,NA,NA,55) | -5.4 Units on a scale | Standard Error 0.78 |
| Placebo | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 6 (n=61,55,25,26,NA) | -5.4 Units on a scale | Standard Error 1.33 |
| Placebo | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 1 (n=65,64,NA,NA,62) | NA Units on a scale | — |
| Placebo | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 3 (n=64,58,NA,NA,55) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 1 (n=65,64,NA,NA,62) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 3 (n=64,58,NA,NA,55) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 6 (n=61,55,25,26,NA) | -5.2 Units on a scale | Standard Error 1.26 |
| Placebo | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 1 (n=65,64,NA,NA,62) | -1.1 Units on a scale | Standard Error 0.64 |
| Placebo | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 6 (n=61,55,25,26,NA) | NA Units on a scale | — |
| Placebo | Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 | Month 3 (n=64,58,NA,NA,55) | -1.9 Units on a scale | Standard Error 0.78 |
Secondary
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (washed out), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 2.7 Units on a scale | Standard Error 0.31 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 2.9 Units on a scale | Standard Error 0.4 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 3.1 Units on a scale | Standard Error 0.38 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 2.8 Units on a scale | Standard Error 0.41 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 2.3 Units on a scale | Standard Error 0.31 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 2.6 Units on a scale | Standard Error 0.39 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 3.2 Units on a scale | Standard Error 0.58 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 4.1 Units on a scale | Standard Error 0.58 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 1.5 Units on a scale | Standard Error 0.39 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 1.0 Units on a scale | Standard Error 0.3 |
Secondary
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (washed out), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 3.3 Units on a scale | Standard Error 0.4 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 4.2 Units on a scale | Standard Error 0.52 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 3.9 Units on a scale | Standard Error 0.48 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 3.2 Units on a scale | Standard Error 0.49 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 2.1 Units on a scale | Standard Error 0.41 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 3.5 Units on a scale | Standard Error 0.54 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 4.3 Units on a scale | Standard Error 0.76 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 4.5 Units on a scale | Standard Error 0.76 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 1.6 Units on a scale | Standard Error 0.49 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 1.2 Units on a scale | Standard Error 0.4 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6
FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless (washed out), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 6.0 Units on a scale | Standard Error 0.66 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 7.1 Units on a scale | Standard Error 0.87 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 7.0 Units on a scale | Standard Error 0.81 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 5.8 Units on a scale | Standard Error 0.82 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 4.4 Units on a scale | Standard Error 0.67 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 6.2 Units on a scale | Standard Error 0.9 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 7.6 Units on a scale | Standard Error 1.28 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | 8.5 Units on a scale | Standard Error 1.28 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 3.0 Units on a scale | Standard Error 0.82 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 2.2 Units on a scale | Standard Error 0.66 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 | Month 6 (n=122,113,56,56,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6
The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. n=number of participants evaluable at each visit.
Time frame: Week 2 and Months 1, 2, 4, and 6
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 1 (128,129,NA,NA,130) | -0.3229 Units on scale | Standard Error 0.04074 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 2 (125,126,NA,NA,121) | -0.4114 Units on scale | Standard Error 0.04311 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Week 2 (129,130,NA,NA,128) | -0.2198 Units on scale | Standard Error 0.03145 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 6 (122,112,56,56,NA) | -0.4365 Units on scale | Standard Error 0.04642 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 4 (125,121,57,58,NA) | -0.4455 Units on scale | Standard Error 0.04489 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 1 (128,129,NA,NA,130) | -0.2279 Units on scale | Standard Error 0.04073 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Week 2 (129,130,NA,NA,128) | -0.1652 Units on scale | Standard Error 0.0316 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 2 (125,126,NA,NA,121) | -0.3131 Units on scale | Standard Error 0.04316 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 4 (125,121,57,58,NA) | -0.3305 Units on scale | Standard Error 0.04523 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 6 (122,112,56,56,NA) | -0.3397 Units on scale | Standard Error 0.0472 |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Week 2 (129,130,NA,NA,128) | NA Units on scale | — |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 4 (125,121,57,58,NA) | -0.3836 Units on scale | Standard Error 0.06443 |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 2 (125,126,NA,NA,121) | NA Units on scale | — |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 1 (128,129,NA,NA,130) | NA Units on scale | — |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 6 (122,112,56,56,NA) | -0.4808 Units on scale | Standard Error 0.0668 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 4 (125,121,57,58,NA) | -0.3918 Units on scale | Standard Error 0.06418 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 2 (125,126,NA,NA,121) | NA Units on scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 6 (122,112,56,56,NA) | -0.4157 Units on scale | Standard Error 0.06665 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Week 2 (129,130,NA,NA,128) | NA Units on scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 1 (128,129,NA,NA,130) | NA Units on scale | — |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 6 (122,112,56,56,NA) | NA Units on scale | — |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Week 2 (129,130,NA,NA,128) | -0.0655 Units on scale | Standard Error 0.03133 |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 2 (125,126,NA,NA,121) | -0.1620 Units on scale | Standard Error 0.04317 |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 4 (125,121,57,58,NA) | NA Units on scale | — |
| Placebo | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 | Month 1 (128,129,NA,NA,130) | -0.1481 Units on scale | Standard Error 0.04038 |
Secondary
Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6
The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). n=number of participants evaluable at each visit.
Time frame: Months 1, 3, and 6
Population: All participants who were randomized, received at least 1 dose of study drug with baseline PGA-PsO \>0, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 1 (n=120,122,NA,NA,125) | -0.5 Units on a scale | Standard Error 0.07 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 6 (n=116,108,55,51,NA) | -0.9 Units on a scale | Standard Error 0.08 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 3 (n=112,116,NA,NA,112) | -0.7 Units on a scale | Standard Error 0.08 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 3 (n=112,116,NA,NA,112) | -1.1 Units on a scale | Standard Error 0.08 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 1 (n=120,122,NA,NA,125) | -0.8 Units on a scale | Standard Error 0.07 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 6 (n=116,108,55,51,NA) | -1.1 Units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 3 (n=112,116,NA,NA,112) | NA Units on a scale | — |
| Placebo | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 1 (n=120,122,NA,NA,125) | NA Units on a scale | — |
| Placebo | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 6 (n=116,108,55,51,NA) | -1.0 Units on a scale | Standard Error 0.12 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 1 (n=120,122,NA,NA,125) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 6 (n=116,108,55,51,NA) | -1.0 Units on a scale | Standard Error 0.13 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 3 (n=112,116,NA,NA,112) | NA Units on a scale | — |
| Placebo | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 3 (n=112,116,NA,NA,112) | -0.4 Units on a scale | Standard Error 0.08 |
| Placebo | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 1 (n=120,122,NA,NA,125) | -0.2 Units on a scale | Standard Error 0.07 |
| Placebo | Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 | Month 6 (n=116,108,55,51,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6
BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug with presence of spondylitis at screening and baseline BASDAI score \>0 cm, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 3 (n=26,22,NA,NA,19) | -2.26 cm | Standard Error 0.465 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 1 (n=26,25,NA,NA,22) | -2.04 cm | Standard Error 0.4 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 6 (n=25,22,8,10,NA) | -2.02 cm | Standard Error 0.463 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 1 (n=26,25,NA,NA,22) | -1.26 cm | Standard Error 0.412 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 3 (n=26,22,NA,NA,19) | -1.92 cm | Standard Error 0.49 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 6 (n=25,22,8,10,NA) | -1.56 cm | Standard Error 0.489 |
| Placebo | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 3 (n=26,22,NA,NA,19) | NA cm | — |
| Placebo | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 1 (n=26,25,NA,NA,22) | NA cm | — |
| Placebo | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 6 (n=25,22,8,10,NA) | -2.26 cm | Standard Error 0.756 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 1 (n=26,25,NA,NA,22) | NA cm | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 6 (n=25,22,8,10,NA) | -3.05 cm | Standard Error 0.701 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 3 (n=26,22,NA,NA,19) | NA cm | — |
| Placebo | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 1 (n=26,25,NA,NA,22) | -0.34 cm | Standard Error 0.415 |
| Placebo | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 6 (n=25,22,8,10,NA) | NA cm | — |
| Placebo | Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 | Month 3 (n=26,22,NA,NA,19) | -1.00 cm | Standard Error 0.506 |
Secondary
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.13 Units on a scale | Standard Error 0.043 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.16 Units on a scale | Standard Error 0.046 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.19 Units on a scale | Standard Error 0.044 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.20 Units on a scale | Standard Error 0.045 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.21 Units on a scale | Standard Error 0.043 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.20 Units on a scale | Standard Error 0.048 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.17 Units on a scale | Standard Error 0.068 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.31 Units on a scale | Standard Error 0.068 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.12 Units on a scale | Standard Error 0.045 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.10 Units on a scale | Standard Error 0.042 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.15 Units on a scale | Standard Error 0.035 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.15 Units on a scale | Standard Error 0.04 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.17 Units on a scale | Standard Error 0.038 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.15 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.10 Units on a scale | Standard Error 0.036 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.15 Units on a scale | Standard Error 0.042 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.23 Units on a scale | Standard Error 0.059 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.32 Units on a scale | Standard Error 0.059 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.05 Units on a scale | Standard Error 0.039 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.08 Units on a scale | Standard Error 0.035 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.26 Units on a scale | Standard Error 0.038 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 6 (n=121,112,56,55,NA) | -0.34 Units on a scale | Standard Error 0.045 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.32 Units on a scale | Standard Error 0.043 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.29 Units on a scale | Standard Error 0.044 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.25 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 6 (n=121,112,56,55,NA) | -0.31 Units on a scale | Standard Error 0.047 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 6 (n=121,112,56,55,NA) | -0.42 Units on a scale | Standard Error 0.066 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 6 (n=121,112,56,55,NA) | -0.34 Units on a scale | Standard Error 0.067 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.12 Units on a scale | Standard Error 0.044 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.11 Units on a scale | Standard Error 0.038 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 | Month 6 (n=121,112,56,55,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 6 (n=120,112,56,55,NA) | -0.19 Units on a scale | Standard Error 0.04 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | -0.11 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | -0.15 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | -0.15 Units on a scale | Standard Error 0.04 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | -0.14 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 6 (n=120,112,56,55,NA) | -0.15 Units on a scale | Standard Error 0.042 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 6 (n=120,112,56,55,NA) | -0.19 Units on a scale | Standard Error 0.058 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 6 (n=120,112,56,55,NA) | -0.17 Units on a scale | Standard Error 0.059 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | -0.04 Units on a scale | Standard Error 0.039 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | -0.03 Units on a scale | Standard Error 0.038 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 | Month 6 (n=120,112,56,55,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.30 Units on a scale | Standard Error 0.047 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.23 Units on a scale | Standard Error 0.042 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.22 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.19 Units on a scale | Standard Error 0.039 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.25 Units on a scale | Standard Error 0.048 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.22 Units on a scale | Standard Error 0.042 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.39 Units on a scale | Standard Error 0.068 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA Units on a scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | -0.34 Units on a scale | Standard Error 0.068 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | -0.15 Units on a scale | Standard Error 0.043 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | -0.17 Units on a scale | Standard Error 0.039 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | NA Units on a scale | — |
Secondary
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6
The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,128) | 9.76 mm | Standard Error 1.565 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | 12.14 mm | Standard Error 1.87 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 3 (n=124,119,NA,NA,117) | 8.62 mm | Standard Error 1.853 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 3 (n=124,119,NA,NA,117) | 12.33 mm | Standard Error 1.896 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,128) | 9.58 mm | Standard Error 1.574 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | 12.63 mm | Standard Error 1.945 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 3 (n=124,119,NA,NA,117) | NA mm | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,128) | NA mm | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | 15.68 mm | Standard Error 2.736 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,128) | NA mm | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | 15.32 mm | Standard Error 2.748 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 3 (n=124,119,NA,NA,117) | NA mm | — |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 3 (n=124,119,NA,NA,117) | 2.64 mm | Standard Error 1.896 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,128) | 3.59 mm | Standard Error 1.557 |
| Placebo | Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 | Month 6 (n=122,112,56,55,NA) | NA mm | — |
Secondary
Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6
Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, and 6
Population: All participants who were randomized, received at least 1 dose of study drug with baseline LEI \>0, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 1 (n=82,95,NA,NA,91) | -1.0 Units of scale | Standard Error 0.19 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 3 (n=79,86,NA,NA,82) | -1.3 Units of scale | Standard Error 0.19 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 6 (n=77,84,38,41,NA) | -1.5 Units of scale | Standard Error 0.19 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 6 (n=77,84,38,41,NA) | -1.6 Units of scale | Standard Error 0.18 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 1 (n=82,95,NA,NA,91) | -0.8 Units of scale | Standard Error 0.18 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 3 (n=79,86,NA,NA,82) | -1.3 Units of scale | Standard Error 0.18 |
| Placebo | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 6 (n=77,84,38,41,NA) | -1.4 Units of scale | Standard Error 0.26 |
| Placebo | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 3 (n=79,86,NA,NA,82) | NA Units of scale | — |
| Placebo | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 1 (n=82,95,NA,NA,91) | NA Units of scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 1 (n=82,95,NA,NA,91) | NA Units of scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 3 (n=79,86,NA,NA,82) | NA Units of scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 6 (n=77,84,38,41,NA) | -1.3 Units of scale | Standard Error 0.26 |
| Placebo | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 1 (n=82,95,NA,NA,91) | -0.5 Units of scale | Standard Error 0.18 |
| Placebo | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 6 (n=77,84,38,41,NA) | NA Units of scale | — |
| Placebo | Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 | Month 3 (n=79,86,NA,NA,82) | -0.5 Units of scale | Standard Error 0.19 |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher bodily pain domain score represents less bodily pain. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | 6.86 T-scores | Standard Error 0.634 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 7.60 T-scores | Standard Error 0.848 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 7.00 T-scores | Standard Error 0.786 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 7.59 T-scores | Standard Error 0.799 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | 6.39 T-scores | Standard Error 0.638 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 7.69 T-scores | Standard Error 0.876 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 8.15 T-scores | Standard Error 1.234 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 10.48 T-scores | Standard Error 1.236 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 2.10 T-scores | Standard Error 0.804 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 1 (n=127,128,NA,NA,129) | 2.31 T-scores | Standard Error 0.633 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher general health domain score represents better general health perceptions. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 3.24 T-scores | Standard Error 0.529 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 6 (n=121,111,56,56,NA) | 3.88 T-scores | Standard Error 0.695 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 3.67 T-scores | Standard Error 0.639 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 3.92 T-scores | Standard Error 0.651 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 3.74 T-scores | Standard Error 0.535 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 6 (n=121,111,56,56,NA) | 4.46 T-scores | Standard Error 0.719 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 6 (n=121,111,56,56,NA) | 6.00 T-scores | Standard Error 1.01 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 6 (n=121,111,56,56,NA) | 5.34 T-scores | Standard Error 1.01 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 2.45 T-scores | Standard Error 0.651 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 2.29 T-scores | Standard Error 0.527 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 | Month 6 (n=121,111,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better mental health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | 4.09 T-scores | Standard Error 0.74 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 5.36 T-scores | Standard Error 0.878 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 4.94 T-scores | Standard Error 0.875 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 4.28 T-scores | Standard Error 0.879 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | 4.19 T-scores | Standard Error 0.738 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 5.37 T-scores | Standard Error 0.902 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 5.37 T-scores | Standard Error 1.265 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 6.47 T-scores | Standard Error 1.259 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 2.97 T-scores | Standard Error 0.88 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | 2.33 T-scores | Standard Error 0.725 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher mental health domain score represents better mental health functioning. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 3.80 T-scores | Standard Error 0.737 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 4.38 T-scores | Standard Error 0.854 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 4.36 T-scores | Standard Error 0.852 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 4.11 T-scores | Standard Error 0.867 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 4.41 T-scores | Standard Error 0.743 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 4.98 T-scores | Standard Error 0.884 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 5.06 T-scores | Standard Error 1.245 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 5.67 T-scores | Standard Error 1.241 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 2.11 T-scores | Standard Error 0.868 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 1.73 T-scores | Standard Error 0.732 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | 4.65 T-scores | Standard Error 0.543 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 5.71 T-scores | Standard Error 0.751 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 5.18 T-scores | Standard Error 0.684 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 5.34 T-scores | Standard Error 0.687 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | 3.98 T-scores | Standard Error 0.542 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 5.00 T-scores | Standard Error 0.768 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 6.45 T-scores | Standard Error 1.076 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | 6.98 T-scores | Standard Error 1.074 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 1.77 T-scores | Standard Error 0.689 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 1 (n=124,127,NA,NA,129) | 1.70 T-scores | Standard Error 0.534 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 | Month 6 (n=118,110,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 10 items of the physical functioning scale represent levels & kinds of limitations between extremes of physical activities, including lifting & carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence & extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher physical functioning domain score represents better physical functioning. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 3.97 T-scores | Standard Error 0.583 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 5.39 T-scores | Standard Error 0.795 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 5.00 T-scores | Standard Error 0.721 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 4.08 T-scores | Standard Error 0.732 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 3.10 T-scores | Standard Error 0.587 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 3.88 T-scores | Standard Error 0.818 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 5.89 T-scores | Standard Error 1.153 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | 5.60 T-scores | Standard Error 1.149 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 1.69 T-scores | Standard Error 0.734 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 1.55 T-scores | Standard Error 0.58 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 | Month 6 (n=121,112,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher role-emotional domain score represents better role-emotional functioning. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 1 (n=125,128,NA,NA,129) | 4.44 T-scores | Standard Error 0.894 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 6 (n=119,111,56,56,NA) | 6.17 T-scores | Standard Error 1.01 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 5.44 T-scores | Standard Error 0.998 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 4.84 T-scores | Standard Error 1.003 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 1 (n=125,128,NA,NA,129) | 3.64 T-scores | Standard Error 0.892 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 6 (n=119,111,56,56,NA) | 5.69 T-scores | Standard Error 1.04 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 1 (n=125,128,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 6 (n=119,111,56,56,NA) | 7.05 T-scores | Standard Error 1.461 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 1 (n=125,128,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 6 (n=119,111,56,56,NA) | 8.00 T-scores | Standard Error 1.455 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 3 (n=121,120,NA,NA,117) | 3.85 T-scores | Standard Error 1.002 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 1 (n=125,128,NA,NA,129) | 3.25 T-scores | Standard Error 0.878 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 | Month 6 (n=119,111,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; & d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher role-physical domain score represents better role-physical functioning. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 1 (n=126,128,NA,NA,129) | 4.22 T-scores | Standard Error 0.63 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 6 (n=120,112,56,56,NA) | 5.58 T-scores | Standard Error 0.857 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | 4.99 T-scores | Standard Error 0.805 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | 5.44 T-scores | Standard Error 0.814 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 1 (n=126,128,NA,NA,129) | 3.55 T-scores | Standard Error 0.633 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 6 (n=120,112,56,56,NA) | 5.24 T-scores | Standard Error 0.881 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 1 (n=126,128,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 6 (n=120,112,56,56,NA) | 7.01 T-scores | Standard Error 1.241 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 1 (n=126,128,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 6 (n=120,112,56,56,NA) | 7.21 T-scores | Standard Error 1.239 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 3 (n=122,120,NA,NA,117) | 2.85 T-scores | Standard Error 0.814 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 1 (n=126,128,NA,NA,129) | 2.24 T-scores | Standard Error 0.623 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 | Month 6 (n=120,112,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher social functioning domain score represents better social functioning. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 4.93 T-scores | Standard Error 0.748 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 5.92 T-scores | Standard Error 0.896 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 6.25 T-scores | Standard Error 0.844 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 5.46 T-scores | Standard Error 0.861 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 4.92 T-scores | Standard Error 0.754 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 5.58 T-scores | Standard Error 0.93 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 5.96 T-scores | Standard Error 1.309 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | 7.90 T-scores | Standard Error 1.305 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 2.89 T-scores | Standard Error 0.861 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 1 (n=128,129,NA,NA,129) | 2.33 T-scores | Standard Error 0.744 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 | Month 6 (n=122,112,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher vitality domain score represents better vitality. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, 6
Population: All participants who were randomized, received at least 1 dose of study drug and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 4.52 T-scores | Standard Error 0.678 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 6 (n=122,111,56,56,NA) | 5.94 T-scores | Standard Error 0.859 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 4.95 T-scores | Standard Error 0.828 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 4.75 T-scores | Standard Error 0.842 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 4.30 T-scores | Standard Error 0.684 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 6 (n=122,111,56,56,NA) | 5.15 T-scores | Standard Error 0.894 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 6 (n=122,111,56,56,NA) | 5.75 T-scores | Standard Error 1.256 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | NA T-scores | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 6 (n=122,111,56,56,NA) | 7.06 T-scores | Standard Error 1.256 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | NA T-scores | — |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 3 (n=124,120,NA,NA,117) | 2.41 T-scores | Standard Error 0.843 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 1 (n=128,128,NA,NA,129) | 1.73 T-scores | Standard Error 0.674 |
| Placebo | Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 | Month 6 (n=122,111,56,56,NA) | NA T-scores | — |
Secondary
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6
The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. n=number of participants evaluable at each visit.
Time frame: Months 1, 3, and 6
Population: All participants who were randomized, received at least 1 dose of study drug with baseline SPARCC Enthesitis Score \>0, and were evaluable.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 1 (n=94,104,NA,NA,98) | -1.9 Units of scale | Standard Error 0.31 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 6 (n=91,93,40,43,NA) | -2.6 Units of scale | Standard Error 0.36 |
| Tofacitinib, 5 mg Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 3 (n=92,96,NA,NA,87) | -2.5 Units of scale | Standard Error 0.34 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 3 (n=92,96,NA,NA,87) | -2.8 Units of scale | Standard Error 0.33 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 1 (n=94,104,NA,NA,98) | -1.9 Units of scale | Standard Error 0.3 |
| Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 6 (n=91,93,40,43,NA) | -3.1 Units of scale | Standard Error 0.35 |
| Placebo | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 3 (n=92,96,NA,NA,87) | NA Units of scale | — |
| Placebo | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 1 (n=94,104,NA,NA,98) | NA Units of scale | — |
| Placebo | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 6 (n=91,93,40,43,NA) | -2.6 Units of scale | Standard Error 0.53 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 1 (n=94,104,NA,NA,98) | NA Units of scale | — |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 6 (n=91,93,40,43,NA) | -2.4 Units of scale | Standard Error 0.51 |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 3 (n=92,96,NA,NA,87) | NA Units of scale | — |
| Placebo | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 3 (n=92,96,NA,NA,87) | -1.3 Units of scale | Standard Error 0.34 |
| Placebo | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 1 (n=94,104,NA,NA,98) | -1.0 Units of scale | Standard Error 0.3 |
| Placebo | Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 | Month 6 (n=91,93,40,43,NA) | NA Units of scale | — |
Secondary
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6
ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.
Time frame: Week 2 and Months 1, 2, 3, 4, and 6
Population: All participants who were randomized and received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=8,13,NA,NA,4) | 6.11 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=23,14,NA,NA,8) | 17.56 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=33,30,NA,NA,14) | 25.19 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=39,37,NA,NA,19) | 29.77 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=50,38,15,21,NA) | 38.17 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=50,39,21,23,NA) | 38.17 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=50,38,15,21,NA) | 28.79 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=50,39,21,23,NA) | 29.55 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=8,13,NA,NA,4) | 9.85 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=33,30,NA,NA,14) | 22.73 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=39,37,NA,NA,19) | 28.03 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=23,14,NA,NA,8) | 10.61 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=39,37,NA,NA,19) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=50,38,15,21,NA) | 22.73 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=8,13,NA,NA,4) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=33,30,NA,NA,14) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=23,14,NA,NA,8) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=50,39,21,23,NA) | 31.82 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=39,37,NA,NA,19) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=23,14,NA,NA,8) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=33,30,NA,NA,14) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=50,39,21,23,NA) | 35.38 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=50,38,15,21,NA) | 32.31 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=8,13,NA,NA,4) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=50,38,15,21,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=33,30,NA,NA,14) | 10.69 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=23,14,NA,NA,8) | 6.11 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=50,39,21,23,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=39,37,NA,NA,19) | 14.50 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=8,13,NA,NA,4) | 3.05 Percentage of participants |
Secondary
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6
ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.
Time frame: Week 2 and Months 1, 2, 3, 4, and 6
Population: All participants who were randomized and received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=2,3,NA,NA,1) | 1.53 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=7,5,NA,NA,3) | 5.34 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=17,13,NA,NA,6) | 12.98 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=22,19,NA,NA,13) | 16.79 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=24,20,6,14,NA) | 18.32 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=28,19,10,12,NA) | 21.37 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=24,20,6,14,NA) | 15.15 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=28,19,10,12,NA) | 14.39 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=2,3,NA,NA,1) | 2.27 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=17,13,NA,NA,6) | 9.85 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=22,19,NA,NA,13) | 14.39 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=7,5,NA,NA,3) | 3.79 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=22,19,NA,NA,13) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=24,20,6,14,NA) | 9.09 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=2,3,NA,NA,1) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=17,13,NA,NA,6) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=7,5,NA,NA,3) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=28,19,10,12,NA) | 15.15 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=22,19,NA,NA,13) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=7,5,NA,NA,3) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=17,13,NA,NA,6) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=28,19,10,12,NA) | 18.46 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=24,20,6,14,NA) | 21.54 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=2,3,NA,NA,1) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 4 (n=24,20,6,14,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 2 (n=17,13,NA,NA,6) | 4.58 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 1 (n=7,5,NA,NA,3) | 2.29 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 6 (n=28,19,10,12,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Month 3 (n=22,19,NA,NA,13) | 9.92 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 | Week 2 (n=2,3,NA,NA,1) | 0.76 Percentage of participants |
Secondary
Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6
ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.
Time frame: Week 2 and Months 1, 2, 4, and 6
Population: All participants who were randomized and received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 4 (n=78,69,30,33,NA) | 59.54 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Week 2 (n=35,38,NA,NA,17) | 26.72 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 6 (n=78,65,33,35,NA) | 59.54 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 1 (n=45,56,NA,NA,29) | 34.35 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 2 (n=63,63,NA,NA,34) | 48.09 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 4 (n=78,69,30,33,NA) | 52.27 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 2 (n=63,63,NA,NA,34) | 47.73 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 1 (n=45,56,NA,NA,29) | 42.42 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 6 (n=78,65,33,35,NA) | 49.24 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Week 2 (n=35,38,NA,NA,17) | 28.79 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 2 (n=63,63,NA,NA,34) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Week 2 (n=35,38,NA,NA,17) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 1 (n=45,56,NA,NA,29) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 4 (n=78,69,30,33,NA) | 45.45 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 6 (n=78,65,33,35,NA) | 50.00 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 6 (n=78,65,33,35,NA) | 53.85 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Week 2 (n=35,38,NA,NA,17) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 4 (n=78,69,30,33,NA) | 50.77 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 2 (n=63,63,NA,NA,34) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 1 (n=45,56,NA,NA,29) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 2 (n=63,63,NA,NA,34) | 25.95 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 4 (n=78,69,30,33,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Week 2 (n=35,38,NA,NA,17) | 12.98 Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 6 (n=78,65,33,35,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 | Month 1 (n=45,56,NA,NA,29) | 22.14 Percentage of participants |
Secondary
Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6
The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders.
Time frame: Week 2, Months 1, 2, 3, 4, and 6
Population: All participants who were randomized and received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Week 2 (n=43,45,NA,NA,23) | 32.82 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 1 (n=56,66,NA,NA,45) | 42.75 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 2 (n=67,72,NA,NA,43) | 51.15 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 3 (n=77,64,NA,NA,38) | 58.78 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 4 (n=74,75,34,38.NA) | 56.49 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 6 (n=77,68,34,36,NA) | 58.78 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 4 (n=74,75,34,38.NA) | 56.82 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 6 (n=77,68,34,36,NA) | 51.52 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Week 2 (n=43,45,NA,NA,23) | 34.09 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 2 (n=67,72,NA,NA,43) | 54.55 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 3 (n=77,64,NA,NA,38) | 48.48 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 1 (n=56,66,NA,NA,45) | 50.00 Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 3 (n=77,64,NA,NA,38) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 4 (n=74,75,34,38.NA) | 51.52 Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Week 2 (n=43,45,NA,NA,23) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 2 (n=67,72,NA,NA,43) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 1 (n=56,66,NA,NA,45) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 6 (n=77,68,34,36,NA) | 51.52 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 3 (n=77,64,NA,NA,38) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 1 (n=56,66,NA,NA,45) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 2 (n=67,72,NA,NA,43) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 6 (n=77,68,34,36,NA) | 55.38 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 4 (n=74,75,34,38.NA) | 58.46 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Week 2 (n=43,45,NA,NA,23) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 4 (n=74,75,34,38.NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 2 (n=67,72,NA,NA,43) | 32.82 Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 1 (n=56,66,NA,NA,45) | 34.35 Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 6 (n=77,68,34,36,NA) | NA Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Month 3 (n=77,64,NA,NA,38) | 29.01 Percentage of participants |
| Placebo | Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 | Week 2 (n=43,45,NA,NA,23) | 17.56 Percentage of participants |
Secondary
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6
PASI determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, and scaling evaluated separately for the head and neck, upper limbs, trunk, and lower limbs and then rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is assigned a numerical score: 0=no involvement; 1=0% to 9%; 2=10% to 29%; 3=30% to 49%; 4=50% to 69%; 5=70% to 89%; 6=90% to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a 75% reduction from baseline in PASI. n=number of responders.
Time frame: Months 1, 3, and 6
Population: All participants who were randomized and received at least 1 dose of study drug with PASI \>0 and BSA ≥3% at baseline.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 1 (n=12,15,NA,NA,5) | 15.00 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 6 (n=27,37,11,14,NA) | 33.75 Percentage of participants |
| Tofacitinib, 5 mg Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 3 (n=17,35,NA,NA,12) | 21.25 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 3 (n=17,35,NA,NA,12) | 43.21 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 1 (n=12,15,NA,NA,5) | 18.52 Percentage of participants |
| Tofacitinib, 10 mg, Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 6 (n=27,37,11,14,NA) | 45.68 Percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 3 (n=17,35,NA,NA,12) | NA Percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 1 (n=12,15,NA,NA,5) | NA Percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 6 (n=27,37,11,14,NA) | 26.19 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 1 (n=12,15,NA,NA,5) | NA Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 6 (n=27,37,11,14,NA) | 31.82 Percentage of participants |
| Placebo/Tofacitinib, 10 mg, Twice Daily | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 3 (n=17,35,NA,NA,12) | NA Percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 3 (n=17,35,NA,NA,12) | 13.95 Percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 1 (n=12,15,NA,NA,5) | 5.81 Percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 | Month 6 (n=27,37,11,14,NA) | NA Percentage of participants |